Erosive lichen planus-like mucositis secondary to Tislelizumab treatment for metastatic cutaneous squamous cell carcinoma with complete remission
Background: Cutaneous squamous cell carcinoma can be a therapeutic challenge when metastatic disease is present. Tislelizumab (anti-PD1) is a new targeted therapy for metastatic cutaneous squamous cell carcinoma whose effectiveness and tolerance are being studied.
Authors
- Ana De La Hera Magallanes
- E. Samaniego-González (ORCID: https://orcid.org/0009-0005-5769-0502)
- Andrés Grau Echevarría (ORCID: https://orcid.org/0000-0003-2557-3107)
- María Criado‐Otero (ORCID: https://orcid.org/0009-0002-4262-0470)
- Patricia Bodas-Gallego
Institutions
- Hospital General Universitario De Valencia (ES)
- Complejo Asistencial Universitario de Palencia (ES)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100712
- Primary Topic
- Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00